Frequent Coamplification and Cooperation between C-MYC and PVT1 Oncogenes Promote Malignant Pleural Mesothelioma

Introduction: Malignant pleural mesothelioma (MPM) is a deadly disease with poor prognosis and few treatment options. We characterized and elucidated the roles of C-MYC and PVT1 involved in the pathogenesis of MPM. Methods: We used small interfering RNA (siRNA)-mediated knockdown in MPM cell lines to determine the effect of C-MYC and PVT1 abrogation on MPM cells undergoing apoptosis, proliferation, and cisplatin sensitivity. We also characterized the expression of microRNAs spanning the PVT1 region in MPM cell lines. Copy number analysis was measured by quantitative polymerase chain reaction and fluorescence in situ hybridization. Results: Copy number analysis revealed copy number gains (CNGs) in chromosomal region 8q24 in six of 12 MPM cell lines. MicroRNA analysis showed high miR-1204 expression in MSTO-211H cell lines with four copies or more of PVT1. Knockdown by siRNA showed increased PARP-C levels in MSTO-211H transfected with siPVT1 but not in cells transfected with siC-MYC. C-MYC and PVT1 knockdown reduced cell proliferation and increased sensitivity to cisplatin. Analysis of the expression of apoptosis-related genes in the MSTO-211H cell line suggested that C-MYC maintains a balance between proapoptotic and antiapoptotic gene expression, whereas PVT1 and, to a lesser extent, miR-1204 up-regulate proapoptotic genes and down-regulate antiapoptotic genes. Fluorescence in situ hybridization analysis of MPM tumor specimens showed a high frequency of both CNGs (11 of 75) and trisomy (three copies; 11 of 75) for the C-MYC locus. Conclusion: Our results suggest that C-MYC and PVT1 CNG promotes a malignant phenotype of MPM, with C-MYC CNG stimulating cell proliferation and PVT1 both stimulating proliferation and inhibiting apoptosis.

[1]  B. Price Analysis of current trends in United States mesothelioma incidence. , 1997, American journal of epidemiology.

[2]  B. Lanphear,et al.  Latent period for malignant mesothelioma of occupational origin. , 1992, Journal of occupational medicine. : official publication of the Industrial Medical Association.

[3]  Stephanie I. Davis,et al.  Incidence and Descriptive Epidemiology of Mesothelioma in the United States, 1999–2002 , 2007, International journal of occupational and environmental health.

[4]  F. Ardissone,et al.  Malignant pleural mesothelioma: clinicopathologic and survival characteristics in a consecutive series of 394 patients. , 2008, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[5]  Wen-Lin Kuo,et al.  Amplification of PVT1 Contributes to the Pathophysiology of Ovarian and Breast Cancer , 2007, Clinical Cancer Research.

[6]  Ramon Silva Martins,et al.  Malignant pleural mesothelioma. , 2012, Journal of the National Comprehensive Cancer Network : JNCCN.

[7]  M. Rocchi,et al.  Identification of a commonly amplified 4.3 Mb region with overexpression of C8FW, but not MYC in MYC-containing double minutes in myeloid malignancies. , 2004, Human molecular genetics.

[8]  G. Evan,et al.  The apoptosis endonuclease and its regulation. , 1992, Seminars in immunology.

[9]  L. You,et al.  Genome-wide screen identifies PVT1 as a regulator of Gemcitabine sensitivity in human pancreatic cancer cells. , 2011, Biochemical and biophysical research communications.

[10]  A. Churg,et al.  Changing trends in US mesothelioma incidence , 2004, Occupational and Environmental Medicine.

[11]  M. Carbone,et al.  The pathogenesis of mesothelioma. , 2006, Seminars in diagnostic pathology.

[12]  Chi V. Dang,et al.  The interplay between MYC and HIF in cancer , 2008, Nature Reviews Cancer.

[13]  Kathryn A. O’Donnell,et al.  The c-Myc target gene network. , 2006, Seminars in cancer biology.

[14]  G. Ceresoli,et al.  Advances in the biology of malignant pleural mesothelioma. , 2011, Cancer treatment reviews.

[15]  M. Malumbres,et al.  Physiological relevance of cell cycle kinases. , 2011, Physiological reviews.

[16]  V. Rusch,et al.  A multi-institutional study confirms the presence and expression of simian virus 40 in human malignant mesotheliomas. , 1998, Cancer research.

[17]  M. Fried,et al.  The DNA region around the c-myc gene and its amplification in human tumour cell lines. , 1994, Oncogene.

[18]  Gerard I. Evan,et al.  Induction of apoptosis in fibroblasts by c-myc protein , 1992, Cell.

[19]  R. Stephens,et al.  The Identification of MicroRNAs in a Genomically Unstable Region of Human Chromosome 8q24 , 2008, Molecular Cancer Research.

[20]  John M. Sedivy,et al.  c-Myc Regulates Cyclin D-Cdk4 and -Cdk6 Activity but Affects Cell Cycle Progression at Multiple Independent Points , 1999, Molecular and Cellular Biology.

[21]  Andrea Cocito,et al.  Genomic targets of the human c-Myc protein. , 2003, Genes & development.

[22]  Letizia Carramusa,et al.  The PVT‐1 oncogene is a Myc protein target that is overexpressed in transformed cells , 2007, Journal of cellular physiology.

[23]  R. Sutherland,et al.  Targeting cyclin-dependent kinase 1 (CDK1) but not CDK4/6 or CDK2 is selectively lethal to MYC-dependent human breast cancer cells , 2014, BMC Cancer.

[24]  Kathryn A. O’Donnell,et al.  Activation of Transferrin Receptor 1 by c-Myc Enhances Cellular Proliferation and Tumorigenesis , 2006, Molecular and Cellular Biology.

[25]  N. Caplen,et al.  Pvt1-encoded microRNAs in oncogenesis , 2008, Retrovirology.

[26]  R. Sutherland,et al.  c-Myc or Cyclin D1 Mimics Estrogen Effects on Cyclin E-Cdk2 Activation and Cell Cycle Reentry , 1998, Molecular and Cellular Biology.

[27]  J. Cleveland,et al.  Constitutive c-myc expression in an IL-3-dependent myeloid cell line suppresses cell cycle arrest and accelerates apoptosis. , 1991, Oncogene.

[28]  K. Coombes,et al.  Increased VEGFR-2 gene copy is associated with chemoresistance and shorter survival in patients with non-small-cell lung carcinoma who receive adjuvant chemotherapy. , 2011, Cancer research.

[29]  J. Bishop,et al.  Identification of a human transcription unit affected by the variant chromosomal translocations 2;8 and 8;22 of Burkitt lymphoma. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[30]  Derek Y. Chiang,et al.  The landscape of somatic copy-number alteration across human cancers , 2010, Nature.

[31]  H. Pass,et al.  Simian virus 40-like DNA sequences in human pleural mesothelioma. , 1994, Oncogene.

[32]  J. M. Adams,et al.  Chromosome 8 breakpoint far 3′ of the c‐myc oncogene in a Burkitt's lymphoma 2;8 variant translocation is equivalent to the murine pvt‐1 locus. , 1986, The EMBO journal.

[33]  T. Möröy,et al.  Miz1 Is Required for Early Embryonic Development during Gastrulation , 2003, Molecular and Cellular Biology.

[34]  Kerstin B. Meyer,et al.  A Functional Variant at a Prostate Cancer Predisposition Locus at 8q24 Is Associated with PVT1 Expression , 2011, PLoS genetics.